Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies

•Bencycloquidium bromide (BCQB) is a novel inhaled anticholinergic bronchodilator with high selectivity for muscarinic M3 receptor.•Pre-clinical studies indicated the potential utility of BCQB for therapy of chronic obstructive pulmonary disease (COPD).•This is the first clinical study of BCQB administered through pulmonary inhalation and provided the initial safety, tolerability and pharmacokinetic profiles of BCQB delivered via pressurised Metered Dose Inhaler (pMDI) in healthy subjects.•The results of this study could enable dose selections and further clinical development in subsequent studies in COPD patients.